Australia: Biotron Anti-HIV Compounds Shown to Act Against HIV
August 23, 2005
The Australian biotechnology firm Biotron Ltd. said recently that its Virion compound was found to work against drug-resistant HIV. CEO Michelle Miller said the treatment worked at later stages than all major HIV drugs currently on the market by preventing infectious viruses from coming outside of the cells. In addition, the compound works against multidrug-resistant HIV, said Miller. Final safety studies are being performed on Virion, and Biotron anticipates "proof of concept" trials -- required for regulatory approval -- by the end of this year. Biotron, which commercializes research out of John Curtain School of Medical Research and the Australian National University in Canberra, said it plans to partner with a major pharmaceutical firm within the next year.
Australian Associated Press
Gilead's Combination of Antiretrovirals Truvada, Sustiva Not Bioequivalent to Two Drugs Alone, Study Says
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.